Psychedelic drugs in the treatment of psychiatric disorders

Iman Badr Ibrahim; Poul Videbech; Sune Puggaard Vogt Straszek

Psychedelic drugs in the treatment of psychiatric disorders

Iman Badr Ibrahim
, Poul Videbech
, Sune Puggaard Vogt Straszek

Abstract

This review aims at RCT's of psychedelics used in the treatment of depression and PTSD. Psilocybin has shown an antidepressant effect in cancer patients that was sustained at 6- and 12-months follow-up. The effect of psilocybin was comparable to escitalopram in one study. Ketamine has shown effect for the treatment of resistant depression. Phase 2 and 3 trials have shown the effect of MDMA on PTSD. No serious adverse events were reported in controlled settings, but larger studies are needed to establish safety and long-term effects.

Bidragets oversatte titel	Not Available
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	185
Udgave nummer	32
ISSN	0041-5782
Status	Udgivet - 7 aug. 2023

Emneord

Humans
Hallucinogens
Psilocybin
Ketamine/adverse effects
Mental Disorders
Escitalopram

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{0a69b31053084a3dbea5eda4476ffb11,

title = "Psychedelic drugs in the treatment of psychiatric disorders",

abstract = "This review aims at RCT's of psychedelics used in the treatment of depression and PTSD. Psilocybin has shown an antidepressant effect in cancer patients that was sustained at 6- and 12-months follow-up. The effect of psilocybin was comparable to escitalopram in one study. Ketamine has shown effect for the treatment of resistant depression. Phase 2 and 3 trials have shown the effect of MDMA on PTSD. No serious adverse events were reported in controlled settings, but larger studies are needed to establish safety and long-term effects.",

keywords = "Humans, Hallucinogens, Psilocybin, Ketamine/adverse effects, Mental Disorders, Escitalopram",

author = "Ibrahim, \{Iman Badr\} and Poul Videbech and Straszek, \{Sune Puggaard Vogt\}",

year = "2023",

month = aug,

day = "7",

language = "Dansk",

volume = "185",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske L{\ae}geforening",

number = "32",

}

TY - JOUR

T1 - Psychedelic drugs in the treatment of psychiatric disorders

AU - Ibrahim, Iman Badr

AU - Videbech, Poul

AU - Straszek, Sune Puggaard Vogt

PY - 2023/8/7

Y1 - 2023/8/7

N2 - This review aims at RCT's of psychedelics used in the treatment of depression and PTSD. Psilocybin has shown an antidepressant effect in cancer patients that was sustained at 6- and 12-months follow-up. The effect of psilocybin was comparable to escitalopram in one study. Ketamine has shown effect for the treatment of resistant depression. Phase 2 and 3 trials have shown the effect of MDMA on PTSD. No serious adverse events were reported in controlled settings, but larger studies are needed to establish safety and long-term effects.

AB - This review aims at RCT's of psychedelics used in the treatment of depression and PTSD. Psilocybin has shown an antidepressant effect in cancer patients that was sustained at 6- and 12-months follow-up. The effect of psilocybin was comparable to escitalopram in one study. Ketamine has shown effect for the treatment of resistant depression. Phase 2 and 3 trials have shown the effect of MDMA on PTSD. No serious adverse events were reported in controlled settings, but larger studies are needed to establish safety and long-term effects.

KW - Humans

KW - Hallucinogens

KW - Psilocybin

KW - Ketamine/adverse effects

KW - Mental Disorders

KW - Escitalopram

UR - https://www.scopus.com/pages/publications/85168615995

M3 - Review

C2 - 37615227

SN - 0041-5782

VL - 185

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 32

ER -

Psychedelic drugs in the treatment of psychiatric disorders

Abstract

Emneord

Andre filer og links

Fingeraftryk

Citationsformater